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On 18 September 2018, the South African (SA) Constitutional Court 
decriminalised the cultivation, possession and use of cannabis in 
private by adults.[1] Section 22A(9)(a)(i) of the Medicines and Related 
Substances Act (Act 101 of 1965) was deemed to be constitutionally 
invalid and the wording needed to be revised by Parliament. 
In February 2019, the SA Health Products Regulatory Authority 
(SAHPRA) issued a communication that the Constitutional 
Court judgment should not be interpreted that persons are allowed 
to prepare cannabis-containing products in a private place and 
sell such products to the public.[2] Provisions of section 14(1) of 
the Medicines and Related Substances Act prohibit the selling of 
unregistered cannabis-containing medicines and products that are 
currently available in SA. In May 2019, this Act was subsequently 
amended by the Minister of Health to exclude from the schedule 
of medicines cannabidiol (CBD)-containing preparations with a 
maximum daily dose ≤20 mg CBD, or raw cannabis materials that do 
not contain >0.0075% CBD and 0.001% delta-9-tetrahydrocannabinol 
(THC).[3] Such preparations should, however, have acceptable low 
risk and health claims. For patients and healthcare practitioners, this 
is in conflict with several outlets and individuals selling cannabis-
containing products (including oils) for medical use, with much 
higher concentrations of CBD and other cannabinoids, and with 
sensational health claims. Few healthcare practitioners are equipped 
with knowledge of the evidence, indications and legislation to 
support the safe use of medical cannabis.[4] In this overview, we 
summarise the indications for the clinical administration of medical 
cannabis, how practitioners may access medical cannabis and the 
current published evidence base. We emphasise that unregulated 
and unregistered cannabis products sold as medical cannabis may 
be of inadequate quality and unverified composition, and are not 
guaranteed to be safe or effective.
Cannabinoids and medical cannabis
The pharmacologically active ligands in medical cannabis are the 
cannabinoids. Over the past years, almost 200 cannabinoids have 
been identified, and the type of cannabinoids differs depending on 
whether they are endogenous (endocannabinoids), plant derived 
(phytocannabinoids) or synthetic.[5-7] The endocannabinoid system 
consists of endogenous lipid-based neurotransmitters that bind to 
cannabinoid receptors expressed widely throughout the body. The 
endocannabinoid system purportedly has two types of receptors, 
CB1 and CB2.[8] CB1 receptors are abundant in the brain and central 
nervous system, but are also found in various other tissues.[9] CB1 
receptors are thought to regulate functions such as memory, nausea 
and vomiting, nociception, sleep and appetite.[8,9] CB2 receptors are 
mostly found in immune cells and the cardiovascular, gastrointestinal 
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and reproductive systems, where it is considered to regulate various 
functions.[9,10] The CB1 and CB2 receptors can be stimulated by 
endocannabinoids, phytocannabinoids or synthetic cannabinoids.[6] 
An important consideration is that the affinity and potency of 
the different cannabinoids for CB1 and CB2 receptors differ such 
that efficacy and safety of one cannabinoid cannot be applied to 
another.[11,12]
Phytocannabinoids are isolated from the Cannabis sativa and 
Cannabis indica plants. THC and CBD are the most widely researched 
phytocannabinoids.[13,14] The psychoactive effects of cannabis have 
been attributed to THC, a major compound of the C. sativa plant, 
while CBD is thought to inhibit these effects.[15] THC functions as an 
agonist with high affinity for both CB1 and CB2 receptors. CBD has 
low affinity for CB1 and CB2, and displays antagonism and inverse 
agonism at these receptors.[16] This implies that the ratio of THC 
and CBD in phytocannabinoids would affect the ultimate clinical 
effect. The strain of cannabis and the cultivation environment, 
such as soil type, irrigation, harvesting and processing, all affect 
the quality and composition of phytocannabinoids.[17,18] Different 
parts of the cannabis plant also have differing concentrations of 
phytocannabinoids, with THC generally being most abundant in the 
flowers and leaves, and CBD in the leaves and stems.[17]
Cannabis products are therefore prone to variability, which 
underpins the strict enforcement of the Medicines and Related 
Substances Act by SAHPRA. Accordingly, unregulated and 
unregistered cannabis products sold as medical cannabis may be 
of inadequate quality and unverified composition, and are not 
guaranteed to be safe or effective. 
Medical cannabis refers to medical products that contain purified 
phytocannabinoids or synthetically derived cannabinoids that have 
been approved by regulatory authorities for medical use.[18] Regulatory 
authorities evaluate medical cannabis products for acceptable 
product variability, and only effective, safe and good-quality products 
complying with good manufacturing practices (GMP) are marketed.[19,20] 
To date, the US Food and Drug Administration (FDA) has approved 
three drugs that contain cannabinoids: a plant-derived CBD solution, 
and two synthetic cannabinoids structurally related to THC, nabilone 
and dronabinol.[18,20] A purified form of THC and CBD in a 1:1 ratio, 
known as nabiximols, has been approved by Health Canada and 
several other countries.[19,21] Approved medical cannabis products on 
the market are oral formulations administered either as capsules, oral 
solutions or oromucosal sprays.[22-26] These standardised preparations 
aim to provide accurate dosing and improve safety.[18] 
Numerous products that contain raw or herbal cannabis, also 
referred to as non-medical products, have not received approval 
from the FDA or other regulatory authorities, such as the European 
Medicines Agency (EMA).[27] Many of these unregulated products 
that are readily available on the market claim to contain only CBD, 
but some contain both CBD and THC that differ in their CBD:THC 
ratios.[19] They also tend to contain higher amounts of psychoactive 
THC and lower amounts of CBD than regulated products.[19] A study 
evaluating the accuracy of labelling of unregulated cannabis-containing 
products in various states in the USA, showed discrepancies between 
the labelling and actual CBD and THC content.[28,29] Unregulated 
cannabis products are freely available on the open market and 
unknowing patients and carers can access these formulations, which 
are sold with unfounded claims regarding efficacy and safety.[30] 
There are >480 constituents in cannabis plants,[31] which can lead to 
significant variation in unregulated cannabis products. Therefore, 
the quality, efficacy and safety of these unregulated products are 
questionable. Importantly, regulatory oversight is essential for 
ongoing safety monitoring of medicines. In 2008, the anti-obesity 
drug rimonabant, a synthetic CB1 antagonist and inverse agonist,[32] 
was withdrawn from the European market after approval in 2006, 
owing to serious central nervous system side-effects.[33] SAHPRA has 
to date approved only one medical cannabis product, dronabinol, for 
marketing in SA,[2] although section 21 approval has been granted 
for some cannabis-containing products registered in other countries 
to meet local clinical needs.[2] Section 21 of the Medicines Act 
allows controlled patient access to medical cannabis registered by 
other regulatory authorities to which SAHPRA aligns. For patients 
to access these medicines that are not registered in SA, a medical 
practitioner needs to apply to SAHPRA to allow specific named 
patient access.
Evidence for the use of medical 
cannabis 
Clinical evidence of the indications for the use of medical cannabis 
is currently supported by a limited evidence base, but the field is 
evolving. Medical cannabis has been shown to be effective for certain 
conditions, but the benefit for most investigated indications is limited, 
in many cases by poor-quality studies, risk of bias and clinically non-
significant findings.[34] The synthetic cannabinoids were mostly 
assessed, as standardisation of phytocannabinoids cannot be ensured, 
and the bioavailability of inhaled cannabis cannot be guaranteed. 
Evidence supporting benefit from the use of medical cannabis exists 
for two drug-resistant childhood forms of epilepsy, Dravet syndrome 
and Lennox-Gastaut syndrome.[35] Three randomised controlled trials 
(RCTs) assessed the effect of a pharmaceutical plant-derived CBD 
solution (Epidiolex), and found that when added as adjuvant therapy 
at the maximum recommended dose, it led to a significant reduction 
in the median frequency of monthly seizures when compared with 
placebo for Lennox-Gastaut syndrome (–18.8%; 95% confi dence 
interval (CI) –31.8 - –4.4; p=0.009),[36,37] and for Dravet syndrome 
(–22.8%; 95% CI –41.1 - –5.4; p=0.01).[38] Based on these findings, 
the FDA approved the plant-derived CBD for Dravet and Lennox-
Gastaut syndromes,[39] and approval by the EMA followed thereafter. 
Long-term therapy with CBD in these epilepsy syndromes has also 
found sustained response and acceptable tolerability.[40,41] Data for 
other types of epilepsy are more limited, but there does appear to be 
benefit for children and adults who have epilepsy that is refractory 
to appropriately dosed antiseizure medications.[42] An open-label 
drug trial established modest evidence for the long-term safety and 
efficacy of CBD administration in patients with medically refractory 
epilepsy associated with cyclin-dependent kinase-like 5 (CDKL5) 
mutations, as well as Aicardi syndrome, 15q11-q13 duplication 
(dup15q), also known as the Prader-Willi/Angelman critical region 
(PWACR), and myoclonic-atonic (Doose) syndromes.[43] However, 
even with this apparent tolerability, clinicians must be aware of 
potential drug-drug interactions between the commonly used 
antiseizure medications and CBD. As an example, clobazam plasma 
concentrations are increased when administered with CBD;[44] this 
potentiation of activity has been noted as an independent factor in 
the apparent improved response of epilepsy to CBD.[45] Studies in 
patients not using clobazam and other interacting medications will 
be important in the future.[45]
For other conditions, there is moderate evidence for the 
management of chemotherapy-induced nausea and vomiting (CINV) 
and multiple sclerosis (MS)-associated spasticity. The synthetic 
cannabinoids dronabinol and nabilone showed the best efficacy in 
reducing CINV, but the risk of bias and lack of consistency of findings 
in trials limit their recommendation.[34,46] Nevertheless, dronabinol 
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and nabilone have both received FDA approval for refractory 
CINV.[23,24] Nabiximols showed a small, but significant, clinical 
improvement in self-reported MS-associated spasticity when 
added to existing therapy.[34,47] Evidence for an overall beneficial 
effect of dronabinol for MS-associated spasticity, however, was 
not found.[48]
Currently, low-level or no convincing evidence exists for chronic 
pain, sleep and weight, or neuropsychiatric disorders. Chronic pain 
studies evaluated a wide spectrum of differing pain conditions, 
outcome measures and cannabinoids, with most studies having a 
high or unclear risk of bias.[34,49,50] Some studies showed significant 
findings, but were not consistent across trials.[34,49] Furthermore, 
improvement in pain scores were generally not clinically significant 
(e.g. a weighted mean difference in pain improvement of 0.46 points 
on an 11-point numeric rating scale (0 - 10)).[34] A trend towards 
benefit for neuropathic pain, however, was suggested.[50]
A meta-analysis[49] pooling 9 RCTs estimated that the number 
needed to treat to benefit for at least a 30% reduction in pain for any 
chronic pain condition was 24 (95% CI 15 - 61). This implies that 
24 patients need to be treated for 1 patient to have a 30% reduction 
in pain. The number needed to harm for any adverse effect was 
6 (95% CI 5 - 8).
Studies assessing cannabis for sleep, weight gain and neuro-
psychiatric disorders (depression, anxiety and psychosis) did not 
show meaningful benefit. These trials had significant limitations 
of low quality, high risk of bias, small sample sizes and/or non-
significant clinical implications.[34]
Harm-benefit ratio
Before prescribing any medicine, the harm-benefit ratio should 
be evaluated. Cannabis is associated with a greater risk of adverse 
effects (AEs) than active and placebo controls, including serious 
AEs and withdrawal from studies due to AEs.[34,49,50] The risk of 
AEs are independent of the type of cannabinoid used. Common 
AEs included gastrointestinal disorders, dizziness, cognitive and 
neuropsychiatric disorders and nausea.[34,49,50] Medical cannabinoids 
(phyto and synthetic) have the potential to alter concomitantly 
administered drug plasma concentrations via drug-drug interactions.[51] 
Conversely, cannabinoid concentrations may in turn be altered by the 
effect of other drugs. This is primarily mediated through inhibition 
or induction of the cytochrome P450 (CYP450) enzymes, but may 
also involve inhibition or induction of conjugation reactions.[51] 
While these interactions pose a potential risk, there is a paucity of 
data to guide clinical decision-making. 
A likely hindrance for access to registered medical cannabis 
is cost. As an example, the CBD solution marketed as Epidiolex 
(accessible via the section 21 process), when added as adjuvant 
therapy to existing antiseizure medication, currently costs ZAR28 528 
for a 100 mL solution. This translates to 2 - 4 weeks of treatment for 
an average-weight child receiving standard doses of Epidiolex. At 
the time of publication, we could not source pricing for dronabinol 
(Marinol or Syndros), nabilone (Cesamet), or nabiximols (Sativex).
Ethical aspects
Ethical concerns related to the medical use of cannabis remain 
complex. The medical profession has the challenging role of 
respecting the autonomy of the patient while balancing the principles 
of beneficence, non-maleficence and justice.[52] This requires 
evidence of efficacy and safety of the various products available, 
which in itself is a contested space. Indiscriminate prescribing of 
a product with THC has the potential to affect cognition, which 
may impair rational decision-making.[53] Harm to the individual 
patient and harm to society then become important considerations. 
There is therefore an ethical duty on the medical practitioner to 
ensure responsible prescribing of THC-containing medical cannabis 
products, and provision of advice to patients. The addition of CBD 
to products containing THC has been shown to reduce the risk of 
impaired cognition.[54,55] Some unregulated cannabis products have 
been assessed and found to vary in their THC and CBD content 
when compared to information on the label, and some commercially 
available products sold as pure CBD contain marked amounts 
of THC.[29,30] This may affect cognition, and where children and 
adolescents are concerned, this is particularly important, given the 
potential for the impact on brain development, cognitive function 
and mental illness.[56] Where good evidence of efficacy exists in the 
context of failed conventional therapy, beneficence will support the 
prescription of a registered safe product.
Legal aspects
In the 1860s, when Indians were brought to work as indentured 
labourers on the sugarcane plantations in Natal, cannabis use 
was introduced in that part of the country. This became a source 
of great concern for their colonial masters, who feared it would 
impact negatively on productivity and work ethic. Consequently, by 
1870, legislation was introduced in the form of Natal’s Coolie Law 
Consolidation, prohibiting the cultivation, possession and use of 
cannabis.[57] By 1922, more stringent laws were in place to prevent 
use. The burden of proof rested with the accused, unlike other 
legislation at the time for alcohol, where the burden of proof rested 
with the accuser.[58] In many respects, a judgement call was made on 
the use of cannabis as a social ill that would corrupt the indentured 
labourers and others in society.[59,60] Hence, the laws were particularly 
punitive, exceeding the legislation on alcohol and smoking that 
were regarded as ‘civilised’ Western substances to use and abuse.[58] 
Given that cannabis was widely used by indigenous people in SA, the 
legislation around cannabis was in keeping with apartheid legislation 
and hence restricted rights to privacy.[59] In the judgment on the 
decriminalisation of cannabis, the High Court stated that much of the 
history of cannabis use in SA ‘is replete with racism’.[1]
The criminalisation of the private use, possession and 
cultivation of cannabis by adults was ruled unconstitutional in 
terms of section 14 of the SA Constitution that protects the right 
to privacy. The Constitutional Court also ruled that sections of the 
Drugs and Drug Trafficking Act 104 of 1992 and the Medicines 
and Related Substances Act violated this right to privacy in a way 
that could not be justified in terms of the limitation clause of 
the Bill of Rights.[1] The SA Central Drug Authority argued that 
alcohol and smoking cause more individual and societal harm 
than cannabis,[61,62] and subsequently the personal use of cannabis 
by adults in private was decriminalised in 2018.[1]
Over the next 2 years, it is anticipated that decriminalisation 
will progress to legalisation and regulation. This will require 
comprehensive guidance on the quality of cannabis production, the 
quantity that is legally permissible for private growth, possession and 
use by adults, how minors and adolescents will be protected, and how 
promotion and enticement will be restricted. Sanctions for violating 
legislation will also need to be determined. These legal developments 
should be accompanied by intense community-engagement strategies 
that raise awareness of the harms and benefits of cannabis use. The 
promotion of public awareness, the development of educational 
material and the provision of rehabilitation services should occur in 
parallel with legal reform.
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Conclusions
High-quality evidence for medical cannabis is still in its infancy. 
Regulatory overview of the use of medical cannabis is essential to 
ensure the availability of safe, effective and good-quality products. 
Overall, the current limited benefits of medical cannabis for most 
indications may be outweighed by the lack of consistent efficacy and 
risk of adverse effects, including multiple drug interactions with no 
data to guide management. Currently, for the majority of proposed 
medical cannabis indications, safer and generally more effective 
pharmacological therapies are regulatorily approved. However, good-
quality data support the use of medical cannabis for rare forms 
of childhood epilepsy resistant to current registered antiseizure 
medications. This may justify facilitated access in SA to medical 
cannabis via section 21. Medical cannabis could also be considered 
for patients with intractable CINV and MS-associated spasticity. 
Unfortunately, the cost of medical cannabis may be prohibitive for 
these patient groups. The regulatory and legal landscape on the use 
of medical cannabis is evolving, and will guide prescription and 
recreational use in the coming years. Until such time, healthcare 
practitioners should be aware of their role in responsible prescription 
and provision of advice to patients.
Key  points
• Few healthcare practitioners are adequately equipped with 
knowledge of the evidence, indications and legislation to support 
the safe use of medical cannabis.
• Grown cannabis contains varying amounts of THC and CBD, 
depending on various cultivation factors.
• Unregulated and unregistered cannabis products may be of 
inadequate quality and unverified composition, and are not 
guaranteed to be safe or effective.
• Convincing evidence exists for the use of registered medical cannabis 
for Dravet and Lennox-Gastaut syndromes. Moderate evidence 
exists for the management of CINV and MS-associated spasticity. 
Currently, low-level or no convincing evidence exists for chronic 
pain, sleep and weight disorders, and neuropsychiatric disorders.
• Cannabis is associated with a greater risk of adverse effects than 
active and placebo controls, including serious adverse effects.
• The evolving regulatory and legal landscape on the use of medical 
cannabis will guide prescription and recreational use in the coming 
years.
Declaration. None.
Acknowledgements. None.
Author contributions. All authors contributed equally.
Funding. None.
Conflicts of interest. None.
1. Minister of Justice and Constitutional Development and Others v Prince (Clarke, Stobbs and Thorpe 
Intervening) (Doctors of Life International Inc as Amicus Curiae); National Director of Public 
Prosecutions and Others v Rubin; National Director of Public Prosecutions and Others v Acton and 
Others 2017. 
2. South African Health Products Regulatory Authority. Status of cannabis-containing products 
(including oils) and the cultivation of cannabis for medicinal use. 2019. https://www.sahpra.org.za/
Publications/DownloadDoc/5576 (accessed 1 July 2019).
3. National Department of Health, South Africa. Medicines and Related Substances Act, 1965 (Act No. 101 
of 1965). Exclusion of certain preparations containing cannabidiol (CBD) from operation of certain 
provisions of the Act. Government Gazette No. 10949:42477. 2019. 
4. Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, 
and concerns surrounding medicinal cannabis – a systematic review. PLoS ONE 2019;14(5):e0216556. 
https://doi.org/10.1371/journal.pone.0216556
5. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: A unified 
critical inventory. Nat Prod Rep 2016;33(12):1357-1392. https://doi.org/10.1039/c6np00074f
6. Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: Current status and 
future implications. Oncotarget 2014;5(15):5852-5872. https://doi.org/10.18632/oncotarget.2233
7. Fisar Z. Phytocannabinoids and endocannabinoids. Curr Drug Abus Rev 2009;2(1):51-75. https://doi.
org/10.2174/1874473710902010051
8. Kaur R, Ambwani S, Singh S. Endocannabinoid system: A multi-facet therapeutic target. Curr Clin 
Pharmacol 2016;11(2):110-117. https://doi.org/10.2174/1574884711666160418105339
9. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in 
the central nervous system. Int J Mol Sci 2018;19(3):833. https://doi.org/10.3390/ijms19030833
10. Svíženská I, Dubový P, Šulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, 
ligands and functional involvement in nervous system structures – a short review. Pharmacol Biochem 
Behav 2008;90(4):501-511. https://doi.org/10.1016/j.pbb.2008.05.010
11. Nahtigal I, Blake A, Hand A, Florentinus-Mefailoski A, Hashemi H, Friedberg J. The pharmacological 
properties of cannabis. J Pain Manage 2016;9(4):481-491. 
12. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical 
cannabis. Pharmacotherapy 2013;33(2):195-209. https://doi.org/10.1002/phar.1187
13. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage 
effects. Br J Pharmacol 2011;163(7):1344-1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x
14. Bow EW, Rimoldi JM. The structure-function relationships of classical cannabinoids: CB1/CB2 
modulation. Perspect Medicin Chem 2016;8:17-39. https://doi.org/10.4137/pmc.s32171
15. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: 
Cannabis potency and cannabinoid profile. PLoS ONE 2013;8(7):e70052. https://doi.org/10.1371/
journal.pone.0070052
16. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. 
LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev 
2010;62(4):588-631. https://doi.org/10.1124/pr.110.003004
17. Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: The plant of the thousand and one molecules. 
Front Plant Sci 2016;7:19. https://doi.org/10.3389/fpls.2016.00019
18. European Monitoring Centre for Drugs and Drug Addiction. Medical Use of Cannabis and 
Cannabinoids: Questions and Answers for Policymaking. Luxembourg: Publications Office of the 
European Union, 2018. http://www.emcdda.europa.eu/system/files/publications/10171/20185584_
TD0618186ENN_PDF.pdf (accessed 1 July 2019).
19. Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and 
cannabinoids. BMJ 2019;365:l1141. https://doi.org/10.1136/bmj.l1141
20. US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products: 
Questions and Answers. Maryland: FDA, 2019. https://www.fda.gov/about-fda/about-website/
website-policies (accessed 4 July 2019).
21. Sativex. Package insert. GW Pharma. 2015. https://www.bayer.ca/omr/online/sativex-pm-en.pdf 
(accessed 4 July 2019).
22. US Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived 
from marijuana to treat rare, severe forms of epilepsy. 2018. https://www.fda.gov/news-events/press-
announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-
severe-forms (accessed 5 July 2019).
23. Marinol. Package insert. AbbVie. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/ -
018651s029lbl.pdf (accessed 5 July 2019).
24. Cesamet. Package insert. Valeant. 2006. https://www.accessdata.fda.gov/drugsatfda_docs/
label/2006/018677s011lbl.pdf (accessed 5 July 2019).
25. Electronic Medicines Compendium (EMC). Sativex Oromucosal Spray – summary of product 
characteristics. Cambridge: GW Pharma, 2018. https://www.medicines.org.uk/emc/product/602/
smpc (accessed 2 July 2019).
26. Epidiolex. Package insert. Greenwich Biosciences. 2018. https://www.accessdata.fda.gov/drugsatfda_
docs/label/2018/210365lbl.pdf (accessed 5 July 2019).
27. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products 
– regulations in Europe and North America. Eur J Intern Med 2018;49:2-6. https://doi.org/10.1016/j.
ejim.2018.01.001
28. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and 
label accuracy in edible medical cannabis products. JAMA 2015;313(24):2491-2493. https://doi.
org/10.1001/jama.2015.6613
29. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy 
of cannabidiol extracts sold online. JAMA 2017;318(17):1708-1709. https://doi.org/10.1001/
jama.2017.11909
30. US Food and Drug Administration. FDA warns companies marketing unproven products, derived 
from marijuana, that claim to treat or cure cancer. 2017. https://www.accessdata.fda.gov/drugsatfda_
docs/label/2018/210365lbl.pdf (accessed 5 July 2019).
31. Cabral GA. Marijuana and cannabinoids. J Cannabis Therapeutics 2001;1(3-4):61-85. https://doi.
org/10.1300/j175v01n03_06
32. Xie S, Furjanic MA, Ferrara JJ, et al. The endocannabinoid system and rimonabant: A new drug with a 
novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as 
potential obesity treatment and other therapeutic use. J Clin Pharm Ther 2007;32(3):209-231. https://
doi.org/10.1111/j.1365-2710.2007.00817.x
33. Sam AH, Salem V, Ghatei MA. Rimonabant: From RIO to ban. J Obes 2011;2011:1-4. https://doi.
org/10.1155/2011/432607
34. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and 
meta-analysis. JAMA 2015;313(24):2456-2473. https://doi.org/10.1001/jama.2015.6358
35. Chen JW, Borgelt LM, Blackmer AB. Cannabidiol: A new hope for patients with 
Dravet or Lennox- Gastaut syndromes. Ann Pharmacother 2019;53(6):603-611. https://doi.
org/10.1177/1060028018822124
36. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut 
syndrome. N Engl J Med 2018;378(20):1888-1897. https://doi.org/10.1056/nejmoa1714631
37. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-
Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. 
Lancet 2018;391(10125):1085-1096. https://doi.org/10.1016/s0140-6736(18)30136-3
38. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet 
syndrome. N Engl J Med 2017;376(21):2011-2020. https://doi.org/10.1056/nejmoa1611618
39. Drugs.com. FDA approves Epidiolex. 2018. https://www.drugs.com/newdrugs/fda-approves-
epidiolex- cannabidiol-lennox-gastaut-syndrome-dravet-syndrome-4769.html (accessed 5 July 2019).
40. Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut 
syndrome: Interim analysis of an open-label extension study. Epilepsia 2019;60(3):419-428. https://
doi.org/10.1111/epi.14670
41. Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet 
syndrome: An open-label extension trial. Epilepsia 2019;60(2):294-302. https://doi.org/10.1111/
epi.14628
42. Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in 
children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia 
2018;59(8):1540-1548. https://doi.org/10.1111/epi.14477
43. Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in 
patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav 
2018;86:131-137. https://doi.org/10.1016/j.yebeh.2018.05.013
44. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol 
in children with refractory epilepsy. Epilepsia 2015;56(8):1246-1251. https://doi.org/10.1111/epi.13060
196       March 2020, Vol. 110, No. 3
IN PRACTICE
45. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: 
An open-label interventional trial. Lancet Neurol 2016;15(3):270-278. https://doi.org/10.1016/s1474-
4422(15)00379-8
46. Tafelski S, Häuser W, Schäfer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-
induced nausea and vomiting – a systematic review of systematic reviews. Schmerz 2016;30(1):14-24. 
https://doi.org/10.1007/s00482-015-0092-3
47. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-
group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory 
spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122-1131. https://doi.org/10.1111/
j.1468-1331.2010.03328.x
48. Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in 
multiple sclerosis: Systematic review and consensus paper. Mult Scler J 2016;22(11):1386-1396. https://
doi.org/10.1177/1352458516643600
49. Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people 
with chronic noncancer pain conditions. Pain 2018;159(10):1932-1954. https://doi.org/10.1097/j.
pain.0000000000001293
50. Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain 
and an overview of general harms. Ann Intern Med 2017;167(5):319-331. https://doi.org/10.7326/
m17-0155
51. Alsherbiny MA, Li CG. Medicinal cannabis – potential drug interactions. Medicines 2019;6(1):3. 
https://doi.org/10.3390/medicines6010003
52. Moodley K. A place for ethics, law and human rights in healthcare. In: Moodley K, ed. Medical Ethics, 
Law, and Human Rights: A South African Perspective. 2nd ed. Pretoria: Van Schaik Publishers, 2017:3-6.
53. Hayry M. Prescribing cannabis: Freedom, autonomy, and values. J Med Ethics 2004;30(4):333-336. 
https://doi.org/10.1136/jme.2002.001347
54. Cohen K, Weinstein A. The effects of cannabinoids on executive functions: Evidence from cannabis 
and synthetic cannabinoids – a systematic review. Brain Sci 2018;8(3):40. https://doi.org/10.3390/
brainsci8030040
55. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms 
and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27(1):19-27. https://doi.
org/10.1177/0269881112460109
56. Shah D, Chand P, Bandawar M, Benegal V, Murthy P. Cannabis induced psychosis and subsequent 
psychiatric disorders. Asian J Psychiatr 2017;30:180-184. https://doi.org/10.1016/j.ajp.2017.10.003
57. Du Toit BM. Cannabis in Africa: A survey of its distribution in Africa, and a study of cannabis use and 
users in multi-ethnic South Africa. Rotterdam: A A Balkema, 1980. 
58. Chanock M. The Making of South African Legal Culture 1902 - 1936: Fear, Favour and Prejudice. 
Cambridge: Cambridge University Press, 2001:20-36.
59. De Vos P. Con Court cannabis judgment: What was the reasoning and what does it mean? 
Constitutionally Speaking, September 2018. https://constitutionallyspeaking.co.za/con-court-
cannabis -judgment-what-was-the-reasoning-and-what-does-it-mean/ (accessed 21 August 2019).
60. Duvall CS. Drug laws, bioprospecting and the agricultural heritage of cannabis in Africa. Space Polity 
2016;20(1):10-25. https://doi.org/10.1080/13562576.2016.1138674
61. Stein D. Position statement on cannabis. S Afr Med J 2016;106(6):569. https://doi.org/10.7196/
samj.2016.v106i6.10863
62. World Health Organization. The Health and Social Effects of Nonmedical Cannabis Use. Geneva: 
WHO, 2016. 
Accepted 10 October 2019.
